Based on SART 2024 data, this calculator estimates your probability of selecting the desired gender based on available embryos.
Note: This estimate assumes at least one embryo will be available for transfer. Actual success depends on your specific medical situation.
Ever wondered if you can pick the gender of your future child during IVF? The short answer is yes, but it’s not as simple as ordering a pink or blue outfit online. In this guide we’ll break down the science, the methods, the legal landscape, and the real‑world outcomes so you know exactly what to expect.
IVF gender selection is the process of using in‑vitro fertilization combined with genetic testing to identify and transfer embryos of a desired sex. It works because embryos develop a set of sex chromosomes (XX for female, XY for male) from the moment the sperm meets the egg. By looking at those chromosomes before implantation, clinics can choose which ones to place in the womb.
Typical IVF involves stimulating the ovaries, retrieving eggs, fertilizing them, and then growing embryos for a few days before transfer. When you add gender selection, an extra step called preimplantation genetic testing (PGT) is performed on day‑3 or day‑5 embryos. The lab biopsies a few cells, runs a quick DNA test, and reports the sex.
Only embryos that match the selected sex are kept for transfer; the rest are usually frozen for future use or discarded according to clinic policy.
There are three medically recognized ways to influence a baby's sex during IVF:
Because IVF already involves handling eggs and sperm in the lab, PGD/PGT is the go‑to choice for most couples who want a specific gender.
All of these steps are routine in modern IVF clinics, but the additional genetic test adds about 1‑2 weeks to the timeline and a modest cost increase.
Sperm sorting separates X‑bearing sperm (which lead to girls) from Y‑bearing sperm (which lead to boys). The most studied method, MicroSort, uses a flow‑cytometry device that stains DNA and splits the cells based on fluorescence. Success rates vary, but studies from the early 2000s reported around 80% accuracy for female selection and 70% for male selection.
Because the sorting happens before fertilization, you can combine the technique with standard IVF or even intra‑uterine insemination (IUI). However, many clinics have moved away from sperm sorting due to the higher reliability of PGD and regulatory hurdles.
Sex selection for non‑medical reasons is legal in many countries, but restrictions exist:
Ethical debates focus on gender bias, societal implications, and the slippery slope toward “designer babies.” Most professional societies recommend thorough counseling and written informed consent.
When PGD/PGT is used, the accuracy exceeds 99% because the test reads the chromosome directly. The limiting factor becomes the number of embryos available. If a cycle produces only one embryo, you either transfer it (regardless of sex) or wait for another retrieval.
Data from the Society for Assisted Reproductive Technology (SART) 2024 report shows that couples who have at least three embryos have a 95% chance of getting the desired gender in the first transfer. The overall live‑birth rate for IVF with PGD is roughly 45% per cycle, similar to standard IVF.
Adding a genetic test does not dramatically increase health risks for the mother or baby. The biopsy is performed on a tiny number of cells, and embryos have been shown to develop normally after the procedure. However, there are a few points to keep in mind:
If your goal is to have a boy or a girl and you’re already planning IVF, gender selection is technically feasible and highly accurate when using PGD/PGT. The biggest hurdles are legal permissions, extra cost, and the emotional weight of making a choice that impacts your future family.
When a clinic uses preimplantation genetic testing, the accuracy of identifying the sex is over 99%. The real limitation is the number of embryos you have. If you only produce one embryo, you can’t choose its sex without discarding it.
No. Countries like the United Kingdom restrict non‑medical gender selection, while the United States generally allows it under professional guidelines. Always check the local regulations before starting a cycle.
Current research shows no increase in major birth defects from the biopsy itself. The procedure is considered safe when performed by experienced embryologists.
In the U.S., the added expense for PGD ranges from $3,000 to $5,000 per cycle. Europe tends to be slightly lower, while some Asian clinics may charge less but could have different success rates.
Key issues include reinforcing gender stereotypes, creating societal imbalances, and the slippery slope toward selecting other traits. Most professional societies ask couples to reflect on motives and undergo counseling before proceeding.